<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">inovmed</journal-id><journal-title-group><journal-title xml:lang="ru">Инновационная медицина Кубани</journal-title><trans-title-group xml:lang="en"><trans-title>Innovative Medicine of Kuban</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2541-9897</issn><publisher><publisher-name>Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35401/2500-0268-2019-15-3-19-24</article-id><article-id custom-type="elpub" pub-id-type="custom">inovmed-206</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Дислипидемия у пациентов с фибрилляцией предсердий на фоне острого коронарного синдрома по данным регистра Краснодарского края</article-title><trans-title-group xml:lang="en"><trans-title>Dyslipidemia in patients with atrial fibrillation on the background of acute coronary syndrome according to the register of the Krasnodar region</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3868-8061</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Татаринцева</surname><given-names>З. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tatarintseva</surname><given-names>Z. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татаринцева Зоя Геннадьевна – заведующая кардиологическим отделением № 4</p><p>350086, Краснодар, ул. 1 Мая, 167</p></bio><bio xml:lang="en"><p>Tatarintseva Zoya G. – Head of Cardiologic Department no. 4</p><p>350086, Krasnodar, 1st May street, 167</p></bio><email xlink:type="simple">tatarintsev_m@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8600-0199</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Космачева</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kosmacheva</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Космачева Елена Дмитриевна – д. м. н., заместитель главного врача по медицинской части; заведующая кафедрой терапии № 1 ФПК и ППС</p></bio><bio xml:lang="en"><p>Kosmacheva Elena D. – Dr. of Sci. (Med.), Chief Medical Officer; Head of Department of Therapy no. 1 ATF</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского Министерства здравоохранения Краснодарского края</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского Министерства здравоохранения Краснодарского края; Кубанский государственный медицинский университет Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1;&#13;
Kuban State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2019</year></pub-date><volume>0</volume><issue>3</issue><fpage>19</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Татаринцева З.Г., Космачева Е.Д., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Татаринцева З.Г., Космачева Е.Д.</copyright-holder><copyright-holder xml:lang="en">Tatarintseva Z.G., Kosmacheva E.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.innovmedkub.ru/jour/article/view/206">https://www.innovmedkub.ru/jour/article/view/206</self-uri><abstract><sec><title>Введение</title><p>Введение. Фибрилляция предсердий (ФП) связана с повышенным риском развития инсульта, смертности и затрат на здравоохранение во всем мире. Прогностическая роль дислипидемии ранее не оценивалась в доступной нам литературе.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Это ретроспективное исследование включало 13244 пациента, последовательно поступившего в ГБУЗ НИИ–ККБ № 1 г. Краснодара с острым коронарным синдромом (ОКС), за период времени с 20 ноября 2015 по 20 ноября 2017 г. Первичные конечные точки были определены как летальность от всех, в том числе от сердечно-сосудистых причин. Вторичные конечные точки были определены как повторный ИМ. Период наблюдения составил 12 месяцев.</p></sec><sec><title>Результаты</title><p>Результаты. В исследуемую группу ОКС + ФП включен 201 пациент. Данная группа пациентов была поделена на 3 подгруппы: пациенты с впервые развившимся эпизодом ФП на фоне ОКС, включившая 52 человека (группа 1); пациенты с постоянной формой ФП, включившая 96 человек (группа 2); пациенты с пароксизмальной или персистирующей формой фибрилляции предсердий, задокументированной до эпизода ОКС, включившая 53 человека (группа 3). В группе 1 достоверно выше был уровень общего холестерина и липопротеинов низкой плотности (ЛПНП). Среди выживших пациентов и выписанных из стационара после эпизода ОКС, а таких составило в группе 1 – 45 человек, в группе 2 – 81 человек и в группе 3 – 47 человек. Через 12 месяцев общая смертность была сопоставима, однако частота развития как фатального, так и нефатального повторного инфаркта миокарда была достоверно выше в группе 1.</p></sec><sec><title>Выводы</title><p>Выводы. Более высокие исходные уровни общего холестерина и ЛПНП связаны с развитием повторного ИМ, что не отражается на общей смертности. Однако эти данные получены на небольшой выборке пациентов и требуют дальнейшей валидизации. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. Atrial fibrillation (AF) is connected with the increased risk of stroke, mortality rate and costs for health care around the world. Earlier the predictive role of a dyslipidemia was not estimated in available literature.</p></sec><sec><title>Material and methods</title><p>Material and methods. This retrospective study included 13,244 patients who consistently referred to Scientific Research Institute – Regional Clinical Hospital no. 1, Krasnodar, with acute coronary syndrome from November 20, 2015 to November 20, 2017. Primary final points were defined both as mortality from all reasons and from the cardiovascular events. Secondary final points were defined as repeated myocardial infarction. Follow up period was 12 months.</p></sec><sec><title>Results</title><p>Results. In the studied group ACS + AF we included 201 patients. This group of patients was divided into 3 subgroups: patients with originally developed AF episode accompanied with acute coronary syndrome, included 52 patients (Group 1), patients with constant AF form, included 96 patients (Group 2) and patients with paroxysmal or persistent atrial fibrillation registered before ACS episode, included 53 patients (Group 3). In Group 1 the level of the general cholesterol and low-density lipoproteins (LDL) was authentically higher. Among the survived and discharged patients after ACS episode there were 45 patients in Group 1, in Group 2 and 3 there were 81 and 47 patients, respectively. In 12 months the general mortality rate was comparable, however, the frequency of lethal and non-lethal myocardial infarction development was authentically higher in Group 1.</p></sec><sec><title>Conclusions</title><p>Conclusions. Higher initial levels of the general cholesterol and LDL are connected with development repeated MI that does not affect the general mortality rate. However, these data are obtained in a small selection of patients and demand a further investigation. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>острый коронарный синдром</kwd><kwd>биомаркеры</kwd><kwd>общий холестерин</kwd><kwd>липопротеины низкой плотности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>acute coronary syndrome</kwd><kwd>biomarkers</kwd><kwd>total cholesterol</kwd><kwd>low-density lipoproteins</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chugh SS, Havmoeller R, Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119.</mixed-citation><mixed-citation xml:lang="en">Chugh SS, Havmoeller R, Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;7;37(38):2893- 2962. doi: 10.1093/eurheartj/ehw210.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;7;37(38):2893- 2962. doi: 10.1093/eurheartj/ehw210.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hijazi Z, Oldgren J, Lindbäck J, et al. A biomarkerbased risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.</mixed-citation><mixed-citation xml:lang="en">Hijazi Z, Oldgren J, Lindbäck J, et al. A biomarkerbased risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018;7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hijazi Z, Wallentin L, Siegbahn A, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093.</mixed-citation><mixed-citation xml:lang="en">Hijazi Z, Wallentin L, Siegbahn A, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082.</mixed-citation><mixed-citation xml:lang="en">Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVORTIMI 53 randomized trial. Circulation. 2014;28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389.</mixed-citation><mixed-citation xml:lang="en">Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVORTIMI 53 randomized trial. Circulation. 2014;28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230-43. doi: 10.1038/nrcardio.2015.2.</mixed-citation><mixed-citation xml:lang="en">Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230-43. doi: 10.1038/nrcardio.2015.2.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;19;487(7407):325-9. doi: 10.1038/nature11260.</mixed-citation><mixed-citation xml:lang="en">Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;19;487(7407):325-9. doi: 10.1038/nature11260.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276-89. doi: 10.1038/nrcardio.2014.26.</mixed-citation><mixed-citation xml:lang="en">Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276-89. doi: 10.1038/nrcardio.2014.26.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ference BA, Ginsberg HN, Graham I, et al. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.</mixed-citation><mixed-citation xml:lang="en">Ference BA, Ginsberg HN, Graham I, et al. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shadi Yaghi, Mitchell SV. Elkind Lipids and Cerebrovascular Disease: Research and Practice. Stroke. 2015;46(11):3322-3328. doi: 10.1161/STROKEAHA.115.011164.</mixed-citation><mixed-citation xml:lang="en">Shadi Yaghi, Mitchell SV. Elkind Lipids and Cerebrovascular Disease: Research and Practice. Stroke. 2015;46(11):3322-3328. doi: 10.1161/STROKEAHA.115.011164.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao YY, Cheng XL, Vaziri ND, et al. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem. 2014;47(15):16-26. doi: 10.1016/j.clinbiochem.2014.07.019.</mixed-citation><mixed-citation xml:lang="en">Zhao YY, Cheng XL, Vaziri ND, et al. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem. 2014;47(15):16-26. doi: 10.1016/j.clinbiochem.2014.07.019.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Alonso A, Yin X, Roetker NS, et al. Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014(7);3(5):e001211. doi: 10.1161/JAHA.114.001211.</mixed-citation><mixed-citation xml:lang="en">Alonso A, Yin X, Roetker NS, et al. Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014(7);3(5):e001211. doi: 10.1161/JAHA.114.001211.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Faye L. Lopez, Sunil K. Agarwal, et al. Blood Lipid Levels, Lipid Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Circ Arrhythm Electrophysiol. 2012(1);5(1):155-162. doi: 10.1161/CIRCEP.111.966804.</mixed-citation><mixed-citation xml:lang="en">Faye L. Lopez, Sunil K. Agarwal, et al. Blood Lipid Levels, Lipid Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Circ Arrhythm Electrophysiol. 2012(1);5(1):155-162. doi: 10.1161/CIRCEP.111.966804.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe H, Tanabe N, Yagihara N, et al. Association between lipid profile and risk of atrial fibrillation. Circ J. 2011;75(12):2767-74.</mixed-citation><mixed-citation xml:lang="en">Watanabe H, Tanabe N, Yagihara N, et al. Association between lipid profile and risk of atrial fibrillation. Circ J. 2011;75(12):2767-74.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mora S, Akinkuolie AO, Sandhu RK, et al. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(4):612-9. doi: 10.1161/CIRCEP.113.001378.</mixed-citation><mixed-citation xml:lang="en">Mora S, Akinkuolie AO, Sandhu RK, et al. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(4):612-9. doi: 10.1161/CIRCEP.113.001378.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Norby FL, Eryd SA, Niemeijer MN, et al. Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFGen Consortium. PLoS One. 2016(21);11(3):e0151932. doi: 10.1371/journal.pone.0151932.</mixed-citation><mixed-citation xml:lang="en">Norby FL, Eryd SA, Niemeijer MN, et al. Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFGen Consortium. PLoS One. 2016(21);11(3):e0151932. doi: 10.1371/journal.pone.0151932.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology. 1999;92(1):21-7. doi: 10.1159/000006942/</mixed-citation><mixed-citation xml:lang="en">Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology. 1999;92(1):21-7. doi: 10.1159/000006942/</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez FL, Agarwal SK, Maclehose RF, et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012;5(1):155–62. doi: 10.1161/CIRCEP.111.966804.</mixed-citation><mixed-citation xml:lang="en">Lopez FL, Agarwal SK, Maclehose RF, et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2012;5(1):155–62. doi: 10.1161/CIRCEP.111.966804.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Alonso A, Yin X, Roetker NS, et al. Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014;3(5):e001211. doi: 10.1161/JAHA.114.001211.</mixed-citation><mixed-citation xml:lang="en">Alonso A, Yin X, Roetker NS, et al. Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014;3(5):e001211. doi: 10.1161/JAHA.114.001211.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Norby FL, Eryd SA, Niemeijer MN, et al. Association of lipid-related genetic variants with the incidence of atrial fibrillation: The AFGen consortium. PLoS One. 2016;11(3):e0151932. doi: 10.1371/journal.pone.0151932.</mixed-citation><mixed-citation xml:lang="en">Norby FL, Eryd SA, Niemeijer MN, et al. Association of lipid-related genetic variants with the incidence of atrial fibrillation: The AFGen consortium. PLoS One. 2016;11(3):e0151932. doi: 10.1371/journal.pone.0151932.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Liu YB, Wu CC, Lee CM, et al. Dyslipidemia is associated with ventricular tachyarrhythmia in patients with acute ST-segment elevation myocardial infarction. J Formos Med Assoc. 2006;105(1):17-24. doi: 10.1016/S0929-6646(09)60104-2.</mixed-citation><mixed-citation xml:lang="en">Liu YB, Wu CC, Lee CM, et al. Dyslipidemia is associated with ventricular tachyarrhythmia in patients with acute ST-segment elevation myocardial infarction. J Formos Med Assoc. 2006;105(1):17-24. doi: 10.1016/S0929-6646(09)60104-2.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Saini HK, Arneja AS, Dhalla NS. Role of cholesterol in cardiovascular dysfunction. Can J Cardiol. 2004;20(3):333-346.</mixed-citation><mixed-citation xml:lang="en">Saini HK, Arneja AS, Dhalla NS. Role of cholesterol in cardiovascular dysfunction. Can J Cardiol. 2004;20(3):333-346.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Renato JA, Rodrigo NC, Kenji N. Choronic and regular use of statin prevents atrial fibrillation in period after cardiac surgery. Arq Bras Cardiol. 2010;95(5):614-620. doi: 10.1590/S0066-782X2010005000129.</mixed-citation><mixed-citation xml:lang="en">Renato JA, Rodrigo NC, Kenji N. Choronic and regular use of statin prevents atrial fibrillation in period after cardiac surgery. Arq Bras Cardiol. 2010;95(5):614-620. doi: 10.1590/S0066-782X2010005000129.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Aydin M, Susam I, Kilicaslan B, et al. Serum cholesterol levels and postoperative atrial fibrillation. J Cardiothorac Surg. 2014;9:69. doi: 10.1186/1749-8090-9-69.</mixed-citation><mixed-citation xml:lang="en">Aydin M, Susam I, Kilicaslan B, et al. Serum cholesterol levels and postoperative atrial fibrillation. J Cardiothorac Surg. 2014;9:69. doi: 10.1186/1749-8090-9-69.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mann DM, Glazer NL, Winter M, et al. A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. Am J Cardiol. 2013;111(10):1437-42. doi: 10.1016/j.amjcard.2013.01.297.</mixed-citation><mixed-citation xml:lang="en">Mann DM, Glazer NL, Winter M, et al. A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. Am J Cardiol. 2013;111(10):1437-42. doi: 10.1016/j.amjcard.2013.01.297.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
